Drug news
NICE confirms positive recommendation for Iluvien for DME
The National Institute for Health and Care Excellence (NICE) has now published final draft guidance recommending Iluvien (fluocinolone acetonide intravitreal implant) from Alimera Sciences, as an option for patients with chronic Diabetic Macular Oedema, a condition that causes blurred or double vision.
Original guidance published by NICE in January 2013 rejected the product on grounds that it did not offer value for money, but a price cut subsequently offered by Alimera helped to change the NICE decision.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.